The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Omvoh has additional ongoing trials in Crohn's disease and UC, including studies to evaluate the long-term efficacy and safety of Omvoh in pediatric patients and adults, and a Phase 4 real-world ...

Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency in patients with developmental and epileptic encephalopathies while ...

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

The most common adverse reactions reported with mirikizumab for Crohn disease were upper respiratory tract infections ... being studied in the open-label extension VIVID-2 study ...

The efficacy and safety of Omvoh are being further assessed in the ongoing, open-label extension VIVID ... Common adverse reactions included upper respiratory tract infections, injection site ...

The presence of RSV in the clinical specimen produces a macroscopic signal in the test; this occurs through the binding of labeled ... and upper vs lower respiratory tract infection) and testing ...

There are some studies of Botox for off-label uses, such as tardive dyskinesia ... For example, in studies, upper respiratory infections (such as the common cold) were more common in children ...

The most common adverse reactions reported were upper respiratory tract infections (28%), injection site reactions ... Omvoh is currently being studied in VIVID-2, an ongoing, open-label extension ...